Mutoharoh, Nunung (2017) ANALISIS EFEKTIVITAS BIAYA ANTIHIPERTENSI ORAL AMLODIPIN DAN CANDESARTAN PADA PASIEN HIPERTENSI RAWAT INAP RSUD PANDAN ARANG BOYOLALI TAHUN 2016. Skripsi thesis, Universitas Setia Budi Surakarta.
Text
skripsi nunung.pdf Download (1MB) |
|
Text
INTI SARI.pdf Download (89kB) |
Abstract
Hypertension was one of the major risk factors for mortality from cardiovascular disorders that resulting in 20-50% of all deaths. Cost healthives in Indonesia was increasing, cost effectiveness analysis was needed to assist in making effective drug selection decisions on benefits and costs. This study aims to determine the most cost-effective antihypertensive in RSUD Pandan Arang Boyolali in 2016. The study was conducted retrospectively on hypertension patients with type of financing BPJS patients class III period from January to December 2016. This research use CEA / Cost Effectiveness Fertilization method. Data taken include: demographic data, length of hospitalization and total cost of therapy based on direct medical costs. The results showed the percentage of therapy effectiveness of amlodipine use of 63,64% and candesartan of 56,25%. The average total cost that used for antihypertensive amlodipine was Rp1.623.542,64 and candesartan was Rp1.559.150,34. Amlodipine therapy group was more cost-effective with ACER value of Rp25.511,35 compared with the candesartan therapy group of Rp27.718,22 in hypertensive patients inpatient at RSUD Pandan Arang Boyolali in 2016. Keywords: Cost effectiveness analysis, antihypertention, hypertension, amlodipine, candesartan
Item Type: | Thesis (Skripsi) |
---|---|
Uncontrolled Keywords: | Cost effectiveness analysis, antihypertention, hypertension, amlodipine, candesartan |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Divisions: | Fakultas Farmasi > Prodi S1 Farmasi |
Depositing User: | Herera Gadys USB |
Date Deposited: | 25 Feb 2019 03:07 |
Last Modified: | 25 Feb 2019 03:07 |
URI: | http://repo.setiabudi.ac.id/id/eprint/1016 |
Actions (login required)
View Item |